Blog
    Regulatory UpdateFor PhysiciansSeptember 12, 2026

    Peptide Regulatory Update: FDA Status and Safety Signals

    Evaluate recent FDA regulatory shifts for BPC-157 and GLP-1 safety signals including NAION and gastrointestinal events for clinical practice.

    Clinical Question

    What is the current regulatory status of commonly compounded peptides, and what safety signals have emerged from clinical trials and postmarketing surveillance?

    Evidence Snapshot

    • Regulatory Classification: Multiple compounds including BPC-157, CJC-1295, and Ipamorelin are currently designated as FDA Category 2 substances.
    • Study Types: Data includes Phase II/III clinical trials (STEP 1, SELECT, SURMOUNT-1, SURMOUNT-5, TRIUMPH-3) and FAERS postmarketing reports.
    • Key Safety Signals: Strong gastrointestinal signals for GLP-1 RAs; emerging signals for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and pulmonary aspiration.
    • Compounding Status: 503A and 503B eligibility has been restricted for several peptides due to immunogenicity and safety concerns.

    What the Research Shows

    Regulatory data as of March 2026 indicates a significant shift in the availability of compounded peptides. The FDA has categorized BPC-157 as a Category 2 bulk substance, citing significant safety risks, immunogenicity concerns, and a lack of safety data. This designation renders it ineligible for routine compounding. Similarly, CJC-1295 and Ipamorelin had their nominations withdrawn and were removed from Category 2 consideration in September 2024, with the FDA citing safety issues such as increased heart rate.

    Thymosin Alpha-1, while approved in over 35 countries as Zadaxin, is not FDA-approved. It was moved to Category 2 in September 2023 and subsequently removed pending advisory review in September 2024, though it remains a substance of concern under interim policy. Clinical trial data for Thymosin Alpha-1 (NCT02867267) in sepsis showed negative results with no reduction in mortality.

    Regarding GLP-1 receptor agonists, clinical trials have demonstrated significant efficacy in weight loss. The STEP 1 trial for Semaglutide reported a 14.9% weight loss, while the SELECT trial showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide showed 22.5% weight loss in the SURMOUNT-1 trial and demonstrated superiority over semaglutide in SURMOUNT-5. Retatrutide reached 24.2% weight loss in Phase II dose-finding studies.

    Safety signals for semaglutide from FAERS data through 2023 (187,757 reports) show strong signals for nausea, vomiting, and delayed gastric emptying. Emerging signals include NAION, with 96 cases detected through December 2024, which initiated a formal EMA review in January 2025. Pulmonary aspiration was also added to the Ozempic label in 2025 due to risks during general anesthesia.

    Mechanism

    Mechanism data for these regulatory shifts focus on safety and pharmacological risks. For BPC-157 and TB-500, the FDA identifies immunogenicity risk and a lack of human exposure data. CJC-1295 is associated with increased heart rate. Semaglutide safety signals are linked to delayed gastric emptying, which contributes to gastrointestinal events and may impact the absorption of oral medications or increase aspiration risk during anesthesia. Hepatobiliary signals such as cholelithiasis are associated with rapid weight loss.

    Limitations of the Evidence

    There is a notable lack of human exposure and safety data for several peptides currently in Category 2, such as TB-500. While semaglutide has extensive postmarketing data, signals like suicidal ideation are currently under evaluation, with existing data not supporting a higher risk versus background rates. Some peptides, such as Selank and Semax, are approved in Russia but lack FDA approval or extensive domestic clinical trial data. The TRIUMPH-3 trial for retatrutide remains active with results not expected until 2025-2026.

    Clinical Takeaway

    Physicians should note that BPC-157, TB-500, GHK-Cu, and GHRP-2 are classified as FDA Category 2 substances due to immunogenicity and safety concerns, impacting their availability via compounding. For GLP-1 RAs, while efficacy is established in Phase III trials, clinicians must monitor for emerging safety signals including NAION and pulmonary aspiration risk.

    This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice. Physicians seeking specific compounding options may consult a peptide therapy clinic or find a doctor for regulatory guidance. The cost of these therapies varies by prescriber and location.

    Sources

    • FDA Regulatory Status Records (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2), March 2026.
    • FAERS Safety Signals (Semaglutide), 2023-2025.
    • Clinical Trial Records: NCT03548935 (STEP 1), NCT03574597 (SELECT), NCT04184622 (SURMOUNT-1), NCT05024032 (SURMOUNT-5), NCT04881706, NCT00451282, NCT02867267.

    Referenced Peptides

    bpc 157semaglutidetirzepatidethymosin alpha 1retatrutide

    This content was generated from TruthTides clinical reference data. It does not constitute medical advice. Always consult a qualified healthcare provider.